TNXP Stock Price, Tonix Pharmaceuticals Holding Quote, Chart

Market Summary

USD0.160.00

Market Closed

0.00%

TNXP Stock Price

View Fullscreen

TNXP RSI Chart

TNXP Valuation

Market Cap

13.5M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

1.74

Price/Free Cashflow

-0.12

TNXP Price/Sales (Trailing)

TNXP Profitability

Operating Margin

38.97%

Return on Equity

-110.55%

Return on Assets

-75.53%

Free Cashflow Yield

-812.94%

TNXP Fundamentals

TNXP Revenue

Revenue (TTM)

7.8M

Rev. Growth (Yr)

278.29%

Rev. Growth (Qtr)

-5.26%

TNXP Earnings

Earnings (TTM)

-116.7M

Earnings Growth (Yr)

13.76%

Earnings Growth (Qtr)

2.33%

Breaking Down TNXP Revenue

Last 30 days

-51.5%

Last 90 days

-48.4%

Trailing 12 Months

-94.4%

How does TNXP drawdown profile look like?

TNXP Financial Health

Current Ratio

2.53

TNXP Investor Care

Shares Dilution (1Y)

729.15%

Diluted EPS (TTM)

-7.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.1M	4.7M	6.2M	7.8M
2022	0	0	0	1.6M
2011	0	0	6.3K	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tonix Pharmaceuticals Holding Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 29, 2022	lederman seth	bought	34,200	1.71	20,000	chief executive officer
Mar 25, 2022	lederman seth	bought	24,500	0.245	100,000	chief executive officer
Sep 28, 2021	lederman seth	bought	7,320	0.61	12,000	chief executive officer
Jun 30, 2021	saenger bradley	acquired	10,583	0.58	18,248	chief financial officer
Jun 30, 2021	sullivan gregory m	acquired	21,167	0.58	36,496	chief medical officer
May 25, 2021	goodman daniel wintner	bought	5,600	1.12	5,000	-
Mar 24, 2021	lederman seth	bought	22,087	1.32	16,733	chief executive officer
Jan 07, 2021	sullivan gregory m	acquired	21,074	0.51	41,322	chief medical officer
Dec 30, 2020	lederman seth	bought	23,800	0.68	35,000	chief executive officer
Aug 31, 2020	treco james	bought	4,895	0.89	5,500	-

Which funds bought or sold TNXP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-8.00	12.00	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-4.00	-	-%
Apr 19, 2024	Tradewinds Capital Management, LLC	unchanged	-	-	1.00	-%
Apr 18, 2024	Barry Investment Advisors, LLC	new	-	2,478	2,478	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	sold off	-100	-15.00	-	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-	-	-%
Apr 01, 2024	Global Wealth Strategies & Associates	sold off	-100	-1.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.83	-53,595	163,394	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	unchanged	-	-2.00	6.00	-%

Are Funds Buying or Selling TNXP?

Are funds buying TNXP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNXP

No. of Funds

Unveiling Tonix Pharmaceuticals Holding Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	6.71%	3,770,000	SC 13G
Feb 14, 2024	alyeska investment group, l.p.	9.99%	5,855,597	SC 13G
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Jan 11, 2024	empery asset management, lp	9.99%	2,313,680	SC 13G
Jan 03, 2024	sabby management, llc	9.99%	5,205,348	SC 13G
Feb 14, 2023	tang capital partners lp	7.4%	4,500,419	SC 13G/A
Dec 27, 2022	tang capital partners lp	7.4%	4,280,916	SC 13G
Jul 08, 2022	blackrock inc.	1.1%	341,736	SC 13G/A
Feb 04, 2022	blackrock inc.	6.2%	30,631,558	SC 13G
Feb 16, 2021	cvi investments, inc.	-	111,250	SC 13G/A

Recent SEC filings of Tonix Pharmaceuticals Holding Corp

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 05, 2024	PRE 14A	PRE 14A
Apr 01, 2024	10-K	Annual Report
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 21, 2024	8-K	Current Report
Mar 20, 2024	8-K	Current Report

Peers (Alternatives to Tonix Pharmaceuticals Holding Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Tonix Pharmaceuticals Holding Corp News

Latest updates

Tonix Pharmaceuticals Holding Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2011Q3	2011Q2	2010Q3	2010Q2
Revenue	-5.3%	3,779	3,989	2,992	1,996	999	2.00	1.00	1.00	2.00
Cost Of Revenue	-100.0%	-	2,374	-	-	-	-	-	-	-
Costs and Expenses	-3.2%	31,108	32,136	29,002	33,902	32,728	-	-	-	-
Operating Expenses	-	-	-	-	-	-	1,014	356	-	-
S&GA Expenses	33.4%	11,622	8,712	7,026	7,391	8,054	-	-	-	-
R&D Expenses	-18.7%	17,119	21,050	21,976	26,511	24,674	-	-	-	-
Interest Expenses	-	-	-	-	-	-	8*	22*	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-
Net Income	2.3%	-27,322	-27,975	-28,356	-33,005	-31,680	-	-	-	-
Net Income Margin	22.9%	-15.02*	-19.47*	-26.17*	-37.55*	-70.71*	-	-	-	-
Free Cashflow	9.6%	-22,778	-25,198	-25,212	-36,710	-26,972	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	10.9%	154	139	160	179	226	243	276	224	241	215	189	184	98.00	68.00	58.00	34.00	15.00	12.00	15.00	20.00	26.00
Current Assets	52.4%	48.00	31.00	51.00	84.00	131	151	192	153	189	195	177	173	88.00	62.00	58.00	33.00	14.00	12.00	14.00	19.00	26.00
Cash Equivalents	273.9%	26.00	7.00	26.00	72.00	120	140	145	140	179	183	166	164	77.00	56.00	55.00	31.00	11.00	10.00	12.00	17.00	25.00
Inventory	2.4%	14.00	13.00	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-0.9%	94.00	95.00	96.00	94.00	94.00	90.00	83.00	70.00	51.00	18.00	10.00	9.00	9.00	4.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	165.2%	49.00	18.00	19.00	14.00	19.00	14.00	16.00	16.00	22.00	13.00	9.00	7.00	11.00	5.00	5.00	3.00	5.00	2.00	2.00	2.00	3.00
Current Liabilities	6.5%	19.00	18.00	18.00	13.00	18.00	13.00	16.00	15.00	22.00	12.00	8.00	6.00	10.00	4.00	5.00	3.00	5.00	2.00	2.00	2.00	3.00
Shareholder's Equity	-12.7%	106	121	140	165	207	229	228	208	219	202	180	177	88.00	63.00	54.00	31.00	9.00	10.00	13.00	18.00	24.00
Retained Earnings	-4.8%	-600	-573	-545	-516	-470	-438	-409	-386	-359	-330	-311	-288	-267	-250	-238	-224	-217	-208	-200	-194	-188
Additional Paid-In Capital	1.7%	706	694	686	683	677	667	638	594	579	532	492	465	355	313	292	256	227	218	213	213	212
Shares Outstanding	230.0%	59.00	18.00	11.00	10.00	12.00	4.00	3.00	3.00	3.00	2.00	2.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	17.00	-	-	-	50.00	-	-	-	384	-	-	-	63,914	-	-	-	7,273	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.5%	-22,340	-23,385	-23,367	-32,911	-22,301	-23,535	-21,171	-31,046	-22,445	-12,946	-19,108	-21,058	-13,914	-15,285	-10,041	-9,326	-6,683	-6,645	-4,713	-8,642	-6,824
Share Based Compensation	-2.0%	2,038	2,079	2,364	2,794	2,716	2,765	2,813	2,620	2,296	2,302	2,089	1,212	871	912	733	360	359	362	431	305	368
Cashflow From Investing	47.5%	-431	-821	-24,019	-3,799	-4,671	-8,820	-14,439	-20,217	-25,622	-7,751	-1,429	-505	-4,534	-4,016	-	-	-5.00	-2.00	-3.00	-7.00	1.00
Cashflow From Financing	548.9%	40,714	6,274	1,029	-11,500	7,229	-4,625	72,177	13,063	43,767	37,961	22,049	108,710	39,859	20,069	34,420	28,757	7,914	4,515	417	73.00	17,187
Buy Backs	-	-	-	-	13,965	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TNXP Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUES:
Product revenue, net	$ 7,768
COSTS AND EXPENSES:
Cost of sales	4,741
Research and development	86,655	81,876
General and administrative	34,752	30,215
Total Operating Expenses	126,148	112,091
Operating loss	(118,380)	(112,091)
Other income, net	1,722	1,873
Net loss	(116,658)	(110,218)
Preferred stock deemed dividend		6,659
Net loss available to common stockholders	$ (116,658)	$ (116,877)
Net loss per common share, basic	$ (6.85)	$ (20.01)
Net loss per common share, diluted	$ (6.85)	$ (20.01)
Weighted average common shares outstanding, basic	17,039,309	5,841,447
Weighted average common shares outstanding, diluted	17,039,309	5,841,447

TNXP Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,948	$ 120,229
Inventory, net	13,639
Prepaid expenses and other current assets	9,181	10,548
Total current assets	47,768	130,777
Property and equipment, net	94,028	93,814
Intangible assets, net	9,743	120
Goodwill	965
Operating lease right-to-use assets	824	715
Other non-current assets	1,129	264
Total assets	154,457	225,690
Current liabilities:
Accounts payable	3,782	8,068
Accrued expenses and other current liabilities	12,482	9,680
Term loan payable, short term	2,350
Lease liability, short term	270	432
Total current liabilities	18,884	18,180

Term loan payable, long term	6,561
Lease liability, long term	632	328
Total liabilities	48,932	18,508
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized Series B Convertible Preferred stock, 0 shares designated as of both December 31, 2023 and 2022; issued and outstanding - None Series A Convertible Preferred stock, 0 shares designated as of both December 31, 2023 and December 31, 2022; issued and outstanding - none
Common stock, $0.001 par value; 160,000,000 shares authorized; 58,614,593 and 12,368,620 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively and 66,329 and 14,999 shares to be issued as of December 31, 2023 and December 31, 2022, respectively	59	12
Additional paid in capital	706,356	677,375
Accumulated deficit	(600,658)	(470,038)
Accumulated other comprehensive loss	(232)	(167)
Total stockholders’ equity	105,525	207,182
Total liabilities and stockholders’ equity	154,457	225,690
Series C Warrant [Member]

Warrant liabilities	14,595
Series D Warrant [Member]

Warrant liabilities	$ 8,260

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

CEO	Dr. Seth Lederman M.D.
WEBSITE	tonixpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions

What is the ticker symbol for Tonix Pharmaceuticals Holding Corp? What does TNXP stand for in stocks?

TNXP is the stock ticker symbol of Tonix Pharmaceuticals Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tonix Pharmaceuticals Holding Corp (TNXP)?

As of Wed Apr 24 2024, market cap of Tonix Pharmaceuticals Holding Corp is 13.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers. The fair value of Tonix Pharmaceuticals Holding Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tonix Pharmaceuticals Holding Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tonix Pharmaceuticals Holding Corp a good stock to buy?

The fair value guage provides a quick view whether TNXP is over valued or under valued. Whether Tonix Pharmaceuticals Holding Corp is cheap or expensive depends on the assumptions which impact Tonix Pharmaceuticals Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNXP.

What is Tonix Pharmaceuticals Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, TNXP's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 1.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNXP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tonix Pharmaceuticals Holding Corp's stock?

In the past 10 years, Tonix Pharmaceuticals Holding Corp has provided -0.804 (multiply by 100 for percentage) rate of return.